139 related articles for article (PubMed ID: 2386891)
21. Mitoxantrone and etoposide: an effective regimen for refractory or relapsed acute myelogenous leukemia.
Lazzarino M; Morra E; Alessandrino EP; Orlandi E; Pagnucco G; Merante S; Bernasconi P; Inverardi D; Bonfichi M; Bernasconi C
Eur J Haematol; 1989 Nov; 43(5):411-6. PubMed ID: 2612614
[TBL] [Abstract][Full Text] [Related]
22. [Preliminary treatment results of relapsed or refractory acute leukemia using two and three drug regimens].
Mariańska B; Apel D; Seferyńska I; Maj S
Wiad Lek; 1998; 51(1-2):42-5. PubMed ID: 9608830
[TBL] [Abstract][Full Text] [Related]
23. High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia.
Hiddemann W; Kreutzmann H; Straif K; Ludwig WD; Mertelsmann R; Donhuijsen-Ant R; Lengfelder E; Arlin Z; Büchner T
Blood; 1987 Mar; 69(3):744-9. PubMed ID: 3469002
[TBL] [Abstract][Full Text] [Related]
24. Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial.
Archimbaud E; Thomas X; Leblond V; Michallet M; Fenaux P; Cordonnier C; Dreyfus F; Troussard X; Jaubert J; Travade P
J Clin Oncol; 1995 Jan; 13(1):11-8. PubMed ID: 7799010
[TBL] [Abstract][Full Text] [Related]
25. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
26. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U
Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688
[TBL] [Abstract][Full Text] [Related]
27. A randomized trial of induction therapy (daunorubicin, vincristine, prednisone versus daunorubicin, vincristine, prednisone, cytarabine and 6-thioguanine) in adult acute lymphoblastic leukemia with long-term follow-up: an Eastern Cooperative Oncology Group Study (E3486).
Wiernik PH; Cassileth PA; Leong T; Hoagland HC; Bennett JM; Paietta E; Oken MM;
Leuk Lymphoma; 2003 Sep; 44(9):1515-21. PubMed ID: 14565653
[TBL] [Abstract][Full Text] [Related]
28. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951.
Wells RJ; Adams MT; Alonzo TA; Arceci RJ; Buckley J; Buxton AB; Dusenbery K; Gamis A; Masterson M; Vik T; Warkentin P; Whitlock JA;
J Clin Oncol; 2003 Aug; 21(15):2940-7. PubMed ID: 12885813
[TBL] [Abstract][Full Text] [Related]
29. Clinical efficacy of mitoxantrone and Ara-C with or without etoposide salvage chemotherapy in adult patients with relapsed or refractory acute lymphoblastic leukemia: retrospective multicenter study of the Korean Adult ALL Working Party.
Ahn JS; Yang DH; Jung SH; Lee JJ; Kim I; Park S; Chung JS; Shin HJ; Kim DY; Lee KH; Moon JH; Sohn SK; Song IC; Jo DY; Joo YD;
Acta Haematol; 2015; 133(1):91-7. PubMed ID: 25171064
[TBL] [Abstract][Full Text] [Related]
30. IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience.
Yavuz S; Paydas S; Disel U; Sahin B
Am J Ther; 2006; 13(5):389-93. PubMed ID: 16988532
[TBL] [Abstract][Full Text] [Related]
31. Intensive postremission chemotherapy without maintenance therapy in adults with acute lymphoblastic leukemia. Dutch Hemato-Oncology Research Group.
Dekker AW; van't Veer MB; Sizoo W; Haak HL; van der Lelie J; Ossenkoppele G; Huijgens PC; Schouten HC; Sonneveld P; Willemze R; Verdonck LF; van Putten WL; Löwenberg B
J Clin Oncol; 1997 Feb; 15(2):476-82. PubMed ID: 9053468
[TBL] [Abstract][Full Text] [Related]
32. Dose-reduced combination of mitoxantrone, etoposide, and cytarabine (miniMEC) for relapsed and refractory acute leukemia.
Yamamoto C; Ito S; Mashima K; Umino K; Minakata D; Yamasaki R; Kawasaki Y; Sugimoto M; Nakano H; Ashizawa M; Okazuka K; Hatano K; Sato K; Oh I; Fujiwara S; Ohmine K; Suzuki T; Muroi K; Kanda Y
Leuk Lymphoma; 2016 Nov; 57(11):2541-7. PubMed ID: 26917050
[TBL] [Abstract][Full Text] [Related]
33. [Multi-agent combination chemotherapy for adult acute lymphoblastic leukemia--individualized chemotherapy].
Uzuka Y; Saito Y; Takahashi H; Komatsu M; Ito T; Toyota T
Gan To Kagaku Ryoho; 1990 Sep; 17(9):1917-23. PubMed ID: 2393309
[TBL] [Abstract][Full Text] [Related]
34. Phase II trial of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide as salvage therapy for refractory or relapsed acute leukemia.
Sung WJ; Kim DH; Sohn SK; Kim JG; Baek JH; Jeon SB; Moon JH; Ahn BM; Lee KB
Jpn J Clin Oncol; 2005 Oct; 35(10):612-6. PubMed ID: 16172175
[TBL] [Abstract][Full Text] [Related]
35. Mitoxantrone and high-dose cytosine arabinoside for the treatment of refractory acute lymphocytic leukemia.
Kantarjian HM; Walters RL; Keating MJ; Estey EH; O'Brien S; Schachner J; McCredie KB; Freireich EJ
Cancer; 1990 Jan; 65(1):5-8. PubMed ID: 2293869
[TBL] [Abstract][Full Text] [Related]
36. Bone marrow transplantation for advanced acute leukemia: a pilot study of high-energy total body irradiation, cyclophosphamide and continuous infusion etoposide.
Bostrom B; Weisdorf DJ; Kim T; Kersey JH; Ramsay NK
Bone Marrow Transplant; 1990 Feb; 5(2):83-9. PubMed ID: 2107007
[TBL] [Abstract][Full Text] [Related]
37. High-dose cytosine arabinoside in combination with mitoxantrone for the treatment of refractory acute myeloid and lymphoblastic leukemia.
Hiddemann W; Kreutzmann H; Straif K; Ludwig WD; Mertelsmann R; Planker M; Donhuijsen-Ant R; Lengfelder E; Arlin Z; Büchner T
Semin Oncol; 1987 Jun; 14(2 Suppl 1):73-7. PubMed ID: 3473685
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of fludarabine, intermittent sequential high-dose cytosine arabinoside, and mitoxantrone (FIS-HAM) salvage therapy in highly resistant acute leukemias.
Kern W; Schleyer E; Braess J; Wittmer E; Ohnesorge J; Unterhalt M; Wörmann B; Büchner T; Hiddemann W
Ann Hematol; 2001 Jun; 80(6):334-9. PubMed ID: 11475146
[TBL] [Abstract][Full Text] [Related]
39. [Chemotherapy of relapsed AML and ALL].
Nishikawa K
Rinsho Ketsueki; 1996 Aug; 37(8):647-50. PubMed ID: 8827871
[No Abstract] [Full Text] [Related]
40. Management of acute promyelocytic leukemia relapse in the ATRA era.
Castagnola C; Lunghi M; Corso A; Tajana M; Zappasodi P; Dabusti M; Lazzarino M; Bernasconi C
Haematologica; 1998 Aug; 83(8):714-7. PubMed ID: 9793255
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
